Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
2.905
-0.105 (-3.49%)
Mar 31, 2025, 10:47 AM EDT - Market open

Company Description

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.

Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.

The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond syndrome, and fanconi anemia, as well as novel fetal hemoglobin inducers, fibrotic disorders, and cardiomyopathies which is in preclinical trial.

It has collaboration and license agreement with MyoKardia, Inc. to identify biological targets that are capable of modulating genes of interest with relevance to cardiomyopathies; and licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy.

Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics logo
Country United States
Founded 2015
IPO Date Jul 18, 2019
Industry Biotechnology
Sector Healthcare
Employees 45
CEO Alexander Sapir

Contact Details

Address:
26 Landsdowne Street
Cambridge, Massachusetts 02139
United States
Phone 617 651 8851
Website fulcrumtx.com

Stock Details

Ticker Symbol FULC
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001680581
CUSIP Number 359616109
ISIN Number US3596161097
Employer ID 47-4839948
SIC Code 2834

Key Executives

Name Position
Alexander C. Sapir Chief Executive Officer, President and Director
Alan A. Musso C.M.A., CPA Chief Financial Officer
Curtis G. Oltmans J.D. Senior Vice President, Chief Legal Officer and Corporate Secretary
Mel Hayes Executive Vice President of Patient Experience
Dr. Bradley E. Bernstein M.D., Ph.D. Founder
Dr. Michael R. Green Founder
Dr. Rudolf Jaenisch M.D., Ph.D. Founder
Dr. Tsun-Huei Lee M.D., Ph.D. Founder
Dr. Danny Reinberg Founder
Gregory Tourangeau Controller and Principal Accounting Officer

Latest SEC Filings

Date Type Title
Mar 4, 2025 8-K Current Report
Feb 25, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 25, 2025 10-K Annual Report
Feb 25, 2025 8-K Current Report
Feb 12, 2025 SCHEDULE 13G Filing
Jan 13, 2025 8-K Current Report
Jan 6, 2025 SCHEDULE 13G Filing
Dec 23, 2024 8-K Current Report
Dec 6, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SCHEDULE 13G Filing